New scan could Fine-Tune radiation for thyroid cancer patients
NCT ID NCT00673010
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a special radioactive substance called 124-Iodine to see how much radiation each thyroid cancer spot in the body receives. The goal was to help doctors decide the right dose of standard treatment (131-Iodine) and avoid giving unnecessary radiation to patients who won't benefit. Twenty adults with thyroid cancer that had spread took part. The approach is a way to gather information to improve future treatment planning.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC THYROID CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Genetic test may spare patients from unnecessary thyroid surgery
- Can a new oral drug outsmart Radioiodine-Resistant thyroid cancer?
- Can an immune booster make radioiodine more effective against thyroid cancer?
- Hidden thyroid cancers may be more common in Graves' disease than thought
- Can math make thyroid hormone therapy more precise?
- Can AI help surgeons see thyroid cancer more clearly?